ArticleJAAD international2022

A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis.

Norito Katoh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.